168 filings
Page 2 of 9
8-K
b0q70vo8
12 Apr 22
Other Events
4:07pm
8-K
mvr4ck
12 Apr 22
Regulation FD Disclosure
9:00am
8-K
l2mwtg do
28 Feb 22
Humanigen Reports Year-End 2021 Financial Results
4:01pm
8-K
pcoivj4sw8z q113
5 Jan 22
Other Events
6:04am
8-K
qzsab i5bs
2 Dec 21
Other Events
8:00am
8-K
9ysw0
26 Nov 21
Departure of Directors or Certain Officers
5:00pm
8-K
9tclzunc
12 Nov 21
Results of Operations and Financial Condition
4:01pm
8-K
ff1k3no
9 Nov 21
Regulation FD Disclosure
8:00am
8-K
qgn9aw5zzdqzyf g23st
20 Oct 21
Humanigen Elects John Hohneker, MD, and Kevin Xie, PhD, to Board of Directors
9:13am
8-K
6jqbxt wta63
5 Oct 21
Departure of Directors or Certain Officers
4:05pm
8-K
rt6w 6zl6l8ds0
14 Sep 21
Regulation FD Disclosure
5:00pm
8-K
bmxvrrq ngiohlknz2k0
10 Sep 21
Other Events
6:01am
8-K
ysxw jdwcl6
12 Aug 21
Humanigen Reports Second Quarter 2021 Financial Results
4:01pm
8-K
3bg 5mjowh
4 Aug 21
Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients
6:04am
8-K
cyz1prs521k7hw21a nr
14 Jul 21
Regulation FD Disclosure
11:58am
8-K
tme4uuxaseepnftau
21 Jun 21
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
olxp08u
17 Jun 21
Humanigen 2021 Annual Stockholder Meeting June 17
6:30am
8-K
coad3yzu7stg3znfy qy
28 May 21
Humanigen Submits Application to FDA for Emergency Use Authorization for Lenzilumab in COVID-19
5:00pm
8-K
oj2r8 sjg5x88pgo
13 May 21
Humanigen Reports First Quarter 2021 Financial Results
4:06pm
8-K
4floc9kqk4
20 Apr 21
Humanigen Reports Positive Data with Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study
5:28pm